Q-omics provides the consensus-scored STX12 profile across patient tissues and cancer cell-line models. STX12 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, STX12 is differentially expressed in 15, with the highest sampling consensus in KICH. Additionally, STX12 protein abundance shows 26,746 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRC, KICH, and LSCC as cancer lineages where STX12 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for STX12 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes STX12 survival associations across molecular data types. STX12 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (2) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible STX12 RNA expression–survival associations across cancer types. High STX12 expression shows unfavorable associations in ACC, KICH, LAML, OV and ESCA, but favorable associations in KIRC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for STX12 RNA expression.
This table summarizes STX12 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 8. The strongest signals are observed in LUAD for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for STX12. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. STX12 shows lower tumor expression in KICH, LUAD, COAD, THCA and LUSC and higher tumor expression in LIHC. The KICH box plot shows higher STX12 RNA expression in normal versus tumor tissue (log2 FC = −1.818, t-test p < 0.001).
This table shows molecular features associated with STX12 in patient tissues and cancer cell lines. In patient samples, STX12 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, STX12 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Leukemia.
